Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are established therapies for glycemic control in type 2 diabetes mellitus (T2DM) as well as weight loss (1,2). Obesity is recognized as a chronic disease and a key component of the cardiometabolic disease spectrum.
Nearly 90% of adult patients with type 2 diabetes have overweight or obesity, defined according to body mass index (BMI) 25.0–29.9 or ≥30.0 kg/m², respectively (1). Treating obesity can improve symptom severity and prognosis among those with type 2 diabetes (2).